cas 1789048-54-9|| where to buy 3-(difluoromethyl)-4-nitro-1H-pyrazole

Produktname:3-(difluoromethyl)-4-nitro-1H-pyrazole

IUPAC Name:3-(difluoromethyl)-4-nitro-1H-pyrazole

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM416928-100mg	in stock	ƙƙƙ
CM416928-250mg	in stock	ƻȷɅ
CM416928-10g	in stock	ƻȷɅɅ
CM416928-25g	in stock	ȷƱɅɅ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1789048-54-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1789048-54-9; Molekulare Formel:C4H3F2N3O2; Schmelzpunkt:-; SMILES-Code:[O-][N+](=O)C1=CNN=C1C(F)F; Dichte:

: Katalognummer:CM416928; Molekulargewicht:163.08; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: KT-474; Kymera announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656). The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera's partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases where there is an opportunity to significantly advance the standard of care, including HS and AD. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.